Teva Pharmaceutical Industries (TEVA) News Today

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported quarterly results that beat analyst expectations and raised its 2026 outlook. Stronger branded-drug sales and upbeat product guidance were positive catalysts, while a discontinued drug trial and lower year-over-year revenue temper the outlook.

• Positive Sentiment: Earnings and guidance beat expectations: Third-quarter adjusted earnings were $0.86 per share versus $0.72 expected, and revenue of about $4.39 billion topped the $4.23 billion consensus. Teva raised its 2026 revenue and product-sales outlook, citing growth in branded medicines. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: UZEDY sales surged: The long-acting schizophrenia treatment generated $85 million in U.S. third-quarter sales, up 96% year over year. Teva lifted its 2026 UZEDY revenue forecast to $290 million–$310 million from $270 million–$290 million. UZEDY Q3 U.S. Net Sales Reach $85M
• Positive Sentiment: Analyst endorsement: TD Cowen raised its price target from $55 to $57 and maintained a Buy rating, signaling confidence in further potential upside. TD Cowen price-target update
• Positive Sentiment: Biosimilar portfolio expansion: Teva secured U.S. commercialization rights to two Samsung Bioepis immunology biosimilars, broadening its product portfolio and potential future revenue sources. Teva and Samsung Bioepis biosimilar agreement
• Negative Sentiment: Drug-development setback and sales pressure: Teva ended its Phase 2 emrusolmin study after an interim review found insufficient efficacy. Quarterly revenue also declined 1.9% year over year, and the company expects U.S. drug-pricing pressure to affect Austedo. Why Teva Is Dropping a Drug Trial While Raising Its Outlook